Pascal Pujol

TL;DR: Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer and was associated with no serious toxic effects and only minimal changes in health-related quality of life.

TL;DR: The characterization of estrogen receptor beta brought new insight into the mechanisms underlying estrogen signaling, and the potential distinct roles of ERalpha and ERbeta expression in carcinogenesis, as suggested by experimental and clinical data are discussed in this review.

TL;DR: It is estimated that the breast cancer lifetime risks for the5% of BRCA1 carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk, and the ovarian cancer lifetime risk is 63% or higher, based on the known cancer risk-modifying loci.

TL;DR: Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC.

TL;DR: In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations.